ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Merck KGaA, Darmstadt, Germany and BeOne Medicines side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Merck KGaA, Darmstadt, GermanyBeOne Medicines
studies on the registry523195
open to participants now1751
phase 3 studies under way719
reach primary completion within a year723
programswith a study of their own in two years1424

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseMerck KGaA, Darmstadt, GermanyBeOne Medicines
Phase 1

Merck KGaA, Darmstadt, Germany: 6 of its 14 programs at phase 1

  1. PARP1 Inhibitor HRS-1167phase 1
  2. M5542phase 1
  3. Anti-MUC-1/Anti-CD40 Bispecific Antibody M0324phase 1
  4. M7437phase 1
  5. Contraceptives, Oral, Combinedphase 1

and 1 more — sign in to see them all

43%
67%
Phase 2

Merck KGaA, Darmstadt, Germany: 2 of its 14 programs at phase 2

  1. mirdametinibphase 2
  2. pimicotinibphase 2
14%

BeOne Medicines: 1 of its 24 programs at phase 2

  1. BGB-45035phase 2
4%
Phase 3

Merck KGaA, Darmstadt, Germany: 3 of its 14 programs at phase 3

  1. enpatoranphase 3
  2. precemtabart tocentecanphase 3
  3. evobrutinibphase 3
21%

BeOne Medicines: 6 of its 24 programs at phase 3

  1. sonrotoclaxphase 3
  2. tislelizumabphase 3
  3. tacabrutidegphase 3
  4. Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033phase 3
  5. CDK4 Inhibitor BGB-43395phase 3

and 1 more — sign in to see them all

25%
Approved, new studies

Merck KGaA, Darmstadt, Germany: 3 of its 14 programs at approved, new studies

  1. nirogacestatapproved, new study
  2. follitropin alfaapproved, new study
  3. lutropin alfaapproved, new study
21%

BeOne Medicines: 1 of its 24 programs at approved, new studies

  1. zanubrutinibapproved, new study
4%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Merck KGaA, Darmstadt, Germany5 readouts · 2 phase 3

Merck KGaA, Darmstadt, Germany, Nov ’26: 1 program whose next study reaches primary completion

  1. mirdametinibphase 2 · Nov 27 · NCT06997276
··

Merck KGaA, Darmstadt, Germany, Feb ’27: 1 program whose next study reaches primary completion

  1. PARP1 Inhibitor HRS-1167phase 1 · Feb 22 · NCT06421935
··

Merck KGaA, Darmstadt, Germany, May ’27: 1 program whose next study reaches primary completion

  1. nirogacestatapproved, new study · May 28 · NCT07170644
···

Merck KGaA, Darmstadt, Germany, Sep ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. follitropin alfaapproved, new study · Sep 30 · NCT07340827
  2. lutropin alfaapproved, new study · Sep 30 · NCT07340827
·
BeOne Medicines10 readouts · 1 phase 3

BeOne Medicines, Nov ’26: 4 programs whose next study reaches primary completion

  1. sonrotoclaxphase 3 · Nov 0 · NCT04973605
  2. tislelizumabphase 3 · Nov 0 · NCT03736889
  3. CDK4 Inhibitor BGB-43395phase 3 · Nov 22 · NCT07820891
  4. tacabrutidegphase 3 · Nov 30 · NCT07005713

BeOne Medicines, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zanubrutinibapproved, new study · Dec 31 · NCT04170283
··

BeOne Medicines, Mar ’27: 1 program whose next study reaches primary completion

  1. Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033phase 3 · Mar 31 · NCT06427941
···

BeOne Medicines, Jul ’27: 2 programs whose next study reaches primary completion

  1. PRMT5 Inhibitor BGB-58067phase 1 · Jul 1 · NCT07712640
  2. Bcl-2 Inhibitor BGB-21447phase 1 · Jul 30 · NCT06756932
·

BeOne Medicines, Sep ’27: 1 program whose next study reaches primary completion

  1. Anti-B7-H4 Antibody Drug Conjugate BG-C9074phase 3 · Sep 28 · NCT06233942

BeOne Medicines, Oct ’27: 1 program whose next study reaches primary completion

  1. BON-107phase 1 · Oct 11 · NCT07934069
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Merck KGaA, Darmstadt, Germany

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

BeOne Medicines

New programs 6

  • BON-C1393phase 1 · first study · Oct 23
  • BON-107phase 1 · first study · Oct 22
  • BG-92505phase 1 · first study · Oct 21
  • BON-106phase 1 · first study · Oct 19 · Neoplasm Metastasis
  • BG-T0920phase 1 · first study · Oct 15 · Lymphoma, Large B-Cell, Diffuse
  • BG-T0050phase 1 · first study · Oct 12 · Lymphoma, Large B-Cell, Diffuse

Reached a new phase 2

Study stopped 0

None

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 6 in all. A program counts in each condition its studies name most.

ConditionMerck KGaA, Darmstadt, GermanyBeOne Medicines
Breast Neoplasmsboth · compare here

Merck KGaA, Darmstadt, Germany in Breast Neoplasms: 2 programs

  1. M7437phase 1
  2. nirogacestatapproved, new study

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Breast Neoplasms in search

Carcinoma, Non-Small-Cell Lungboth · compare here

Merck KGaA, Darmstadt, Germany in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. mirdametinibphase 2
  2. Anti-MUC-1/Anti-CD40 Bispecific Antibody M0324phase 1

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Carcinoma, Non-Small-Cell Lung in search

BeOne Medicines in Carcinoma, Non-Small-Cell Lung: 1 program

  1. tislelizumabphase 3

Their studies: BeOne Medicines’ studies of Carcinoma, Non-Small-Cell Lung in search

Arthritis, Rheumatoidboth · compare here

Merck KGaA, Darmstadt, Germany in Arthritis, Rheumatoid: 1 program

  1. evobrutinibphase 3

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Arthritis, Rheumatoid in search

BeOne Medicines in Arthritis, Rheumatoid: 1 program

  1. BGB-45035phase 2

Their studies: BeOne Medicines’ studies of Arthritis, Rheumatoid in search

Autoimmune Diseasesboth · compare here

Merck KGaA, Darmstadt, Germany in Autoimmune Diseases: 1 program

  1. evobrutinibphase 3

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Autoimmune Diseases in search

BeOne Medicines in Autoimmune Diseases: 1 program

  1. BGB-45035phase 2

Their studies: BeOne Medicines’ studies of Autoimmune Diseases in search

Multiple Myelomaboth · compare here

Merck KGaA, Darmstadt, Germany in Multiple Myeloma: 1 program

  1. nirogacestatapproved, new study

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Multiple Myeloma in search

BeOne Medicines in Multiple Myeloma: 1 program

  1. sonrotoclaxphase 3

Their studies: BeOne Medicines’ studies of Multiple Myeloma in search

Stomach Neoplasmsboth · compare here

Merck KGaA, Darmstadt, Germany in Stomach Neoplasms: 1 program

  1. precemtabart tocentecanphase 3

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Stomach Neoplasms in search

BeOne Medicines in Stomach Neoplasms: 1 program

  1. tislelizumabphase 3

Their studies: BeOne Medicines’ studies of Stomach Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetMerck KGaA, Darmstadt, GermanyBeOne Medicines
BTKevobrutinibrulezanubrutinibrule, tacabrutidegrule
A target, or a pathogen for a vaccine, known for: Merck KGaA, Darmstadt, Germany 9 of 14 · BeOne Medicines 12 of 24 programs (21 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.